| 摘要 |
It is intended to provide a preventive or therapeutic drug for a disease caused by a decrease in lacrimal fluid. More specifically, it is intended to provide a preventive or therapeutic drug for a disease caused by a decrease in lacrimal fluid (dry eye, dry keratoconjunctivitis, keratoconjunctival epithelial damage, a decrease in lacrimation, xerophthalmia, age-related dry eye syndrome, eye damage in Stevens-Johnson syndrome, eye damage in Sjogren syndrome, keratoconjunctival ulcer, dryness in wearing contact lenses or the like), characterized by containing a F3-adrenergic receptor stimulant. Further, it is intended to provide a combination drug, characterized by containing the F3-adrenergic receptor stimulant and a F2-adrenergic receptor stimulant in combination.
|
